Merrimack Pharmaceuticals, Inc. is a privately held biotechnology company based in Cambridge, Massachusetts.  We are dedicated to the discovery and development of innovative therapies for the treatment of autoimmune disease and cancer.  Our goal is to provide patients and physicians with not only the best possible treatments, but to support our pharmaceuticals with the tools to enable the prescription of the right drug for the right patient.

Merrimack is advancing a robust pipeline of clinical and early-stage biologics that represent the next generation of patient-directed, targeted therapies.  Our discovery and development efforts are founded on our proprietary Network Biology research engine and the talents and expertise of our employees.  Our lead product, MM-093, is currently in Phase 2 clinical trials for the treatment of patients with rheumatoid arthritis and psoriasis.